Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 190Leukemia, Lymphocytic, Chronic, B-Cell 69Myelodysplastic Syndromes 48Recurrence 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Mantle-Cell 21Leukemia, Myelomonocytic, Chronic 20Leukemia, Biphenotypic, Acute 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Hematologic Neoplasms 14Lymphoma, Non-Hodgkin 13Lymphoma 13Burkitt Lymphoma 13Lymphoma, B-Cell, Marginal Zone 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms 10Waldenstrom Macroglobulinemia 8Myeloproliferative Disorders 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Neoplasm, Residual 6Leukemia, Myeloid 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4GATA2 Deficiency 4Leukemia, Monocytic, Acute 3Leukemia, B-Cell 3

Interventions

Specimen Handling 7Biopsy 6Cyclophosphamide 5ruxolitinib 4Mycophenolic Acid 4Busulfan 4fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Tacrolimus 3Melphalan 3Injections 3Decitabine 3Cyclosporine 3Azacitidine 3venetoclax 2decitabine and cedazuridine drug combination 2Sirolimus 2Methotrexate 2Granulocyte Colony-Stimulating Factor 2veliparib 1tocilizumab 1tagraxofusp 1posaconazole 1peginterferon alfa-2b 1onvansertib 1merphos 1iadademstat 1gilteritinib 1fedratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × venetoclax × 1 year × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04140487 2026-04-16

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
97 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡